Valuation : Protagonist Therapeutics, Inc.

Market Cap 9.39B 8.1B 7.67B 6.94B 13.03B 897B 13.1B 90.97B 34.99B 456B 35.28B 34.5B 1,442B P/E 2026 *
31.2x
P/E 2027 * -306x
Enterprise Value 8.85B 7.64B 7.23B 6.55B 12.28B 846B 12.35B 85.75B 32.99B 430B 33.25B 32.52B 1,360B EV / Sales 2026 *
16.3x
EV / Sales 2027 * 43.7x
Free-Float
97.68%
Yield 2026 *
-
Yield 2027 * -
1 day+2.08%
1 week-0.42%
Current month+0.29%
1 month-1.21%
3 months+40.10%
6 months+52.68%
Current year+69.66%
1 week 142
Extreme 142
151.18
1 month 141.95
Extreme 141.9479
160.81
Current year 77
Extreme 77
160.81
1 year 57.9
Extreme 57.9
160.81
3 years 13.72
Extreme 13.72
160.81
5 years 6.91
Extreme 6.91
160.81
10 years 4.47
Extreme 4.47
160.81
Manager TitleAgeSince
Chief Executive Officer 69 01/12/2008
Director of Finance/CFO 52 18/04/2022
Chief Tech/Sci/R&D Officer - 01/04/2026
Director TitleAgeSince
Director/Board Member 69 01/12/2008
Chairman 71 19/03/2014
Director/Board Member 69 01/07/2016
Date Insider Type Main position Quantity % Market Cap. Importance
9/3/26 A Don

Chief Executive Officer

-510 0.0008%
8/11/26 A Exercice

Chief Executive Officer

102,717 0.1597%
6/10/26 A Exercice

Director

27,000 0.0420%
Change 5-day change 1-year change 3-year change Capi.($)
+2.08%-0.42%+156.63%+677.85% 9.39B
-0.71%-8.73%-4.56%+9.80% 46.05B
+0.21%-3.37%+403.76%+534.40% 43.59B
+1.74%-3.63%+42.37%+22.59% 42.35B
+1.38%-4.46%+10.38%+79.88% 38.86B
-1.44%-4.76%+10.26%+38.52% 32.24B
+0.87%-2.81% - - 17.16B
+0.75%-0.99%+23.25%+116.71% 16.28B
-0.31%-3.76%+12.33%+30.49% 14.32B
+1.93%-5.14%+81.55%+39.31% 13.03B
Average +0.65%-4.53%+81.77%+172.17% 27.33B
Weighted average by Cap. +0.46%-5.01%+89.82%+149.40%

Financials

2026 *2027 *
Net sales 542M 468M 443M 401M 752M 51.81B 757M 5.25B 2.02B 26.33B 2.04B 1.99B 83.27B 203M 175M 166M 150M 282M 19.43B 284M 1.97B 758M 9.88B 764M 747M 31.23B
Net income 324M 279M 264M 239M 449M 30.93B 452M 3.14B 1.21B 15.72B 1.22B 1.19B 49.72B -32.12M -27.7M -26.21M -23.75M -44.55M -3.07B -44.81M -311M -120M -1.56B -121M -118M -4.93B
Net Debt -538M -464M -439M -398M -746M -51.42B -751M -5.21B -2.01B -26.13B -2.02B -1.98B -82.65B -511M -441M -417M -378M -709M -48.83B -713M -4.95B -1.9B -24.82B -1.92B -1.88B -78.48B
Logo Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. is a biopharmaceutical company with a technology platform that enables de novo discovery of peptide therapeutics. The Company's programs fall into three therapeutic areas: inflammation and immunology (I&I), hematology, and metabolic diseases. Its clinical and pre-clinical programs address biologically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, obesity dual agonist peptide PN-458, oral small molecule hepcidin functional mimetic PN-8047, and IL-4 and amylin programs. The ICOTYDE (icotrokinra) is used for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Rusfertide is an investigational injectable mimetic of the natural hormone hepcidin in development for the treatment of the rare blood disorder polycythemia vera (PV).
Employees
141
Date Price Change Volume
11/09/26 $148.18 +2.08% 476,241
10/09/26 $145.16 +0.05% 543,129
09/09/26 $145.09 -0.58% 530,534
08/09/26 $145.94 +0.15% 700,126
04/09/26 $145.72 -2.07% 501,305
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
148.18USD
Average target price
174.69USD
Spread / Average Target
+17.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTGX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!